BridgeBio Pharma Inc
BBIO47.790USD
+0.420+0.89%
Market hours （ET）Quotes delayed by 15 min
9.07BMarket Cap
LossP/E TTM
More Details of BridgeBio Pharma Inc Company
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.
Company Info
Ticker SymbolBBIO
Company nameBridgeBio Pharma Inc
IPO dateJun 27, 2019
CEODr. Neil Kumar, Ph.D.
Number of employees725
Security typeOrdinary Share
Fiscal year-endJun 27
Address3160 Porter Dr.
CityPALO ALTO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94304
Phone16503919740
Websitehttps://bridgebio.com/
Ticker SymbolBBIO
IPO dateJun 27, 2019
CEODr. Neil Kumar, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Neil Kumar, Ph.D.
Dr. Neil Kumar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
6.16M
+0.09%
Dr. Charles J. Homcy, M.D.
Dr. Charles J. Homcy, M.D.
Lead Director, Chairman of Pharmaceuticals
Lead Director, Chairman of Pharmaceuticals
1.22M
-1.09%
Mr. Ali J. Satvat
Mr. Ali J. Satvat
Independent Director
Independent Director
165.99K
+4.13%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
95.08K
+7.45%
Dr. Thomas Trimarchi, Ph.D.
Dr. Thomas Trimarchi, Ph.D.
President, Chief Financial Officer
President, Chief Financial Officer
57.85K
-26.92%
Mr. Fred Hassan
Mr. Fred Hassan
Lead Independent Director
Lead Independent Director
25.89K
+34.14%
Mr. Ronald J. Daniels, J.D.
Mr. Ronald J. Daniels, J.D.
Independent Director
Independent Director
16.99K
+63.34%
Dr. Randal W. (Randy) Scott, Ph.D.
Dr. Randal W. (Randy) Scott, Ph.D.
Independent Director
Independent Director
15.59K
+73.21%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
13.74K
+92.13%
Dr. Eric Aguiar, M.D.
Dr. Eric Aguiar, M.D.
Independent Director
Independent Director
6.59K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Neil Kumar, Ph.D.
Dr. Neil Kumar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
6.16M
+0.09%
Dr. Charles J. Homcy, M.D.
Dr. Charles J. Homcy, M.D.
Lead Director, Chairman of Pharmaceuticals
Lead Director, Chairman of Pharmaceuticals
1.22M
-1.09%
Mr. Ali J. Satvat
Mr. Ali J. Satvat
Independent Director
Independent Director
165.99K
+4.13%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
95.08K
+7.45%
Dr. Thomas Trimarchi, Ph.D.
Dr. Thomas Trimarchi, Ph.D.
President, Chief Financial Officer
President, Chief Financial Officer
57.85K
-26.92%
Mr. Fred Hassan
Mr. Fred Hassan
Lead Independent Director
Lead Independent Director
25.89K
+34.14%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
Europe Middle East and Africa (EMEA)
77.09M
66.10%
United States
36.86M
31.60%
Asia Pacific (APAC)
2.68M
2.30%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Viking Global Investors LP
9.80%
The Vanguard Group, Inc.
8.68%
Kohlberg Kravis Roberts & Co. L.P.
6.98%
BlackRock Institutional Trust Company, N.A.
5.89%
Janus Henderson Investors
3.78%
Other
64.87%
Shareholders
Shareholders
Proportion
Viking Global Investors LP
9.80%
The Vanguard Group, Inc.
8.68%
Kohlberg Kravis Roberts & Co. L.P.
6.98%
BlackRock Institutional Trust Company, N.A.
5.89%
Janus Henderson Investors
3.78%
Other
64.87%
Shareholder Types
Shareholders
Proportion
Investment Advisor
32.61%
Investment Advisor/Hedge Fund
31.42%
Hedge Fund
15.71%
Private Equity
8.99%
Individual Investor
4.95%
Research Firm
3.23%
Venture Capital
1.89%
Sovereign Wealth Fund
0.56%
Bank and Trust
0.49%
Other
0.16%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
620
190.27M
100.20%
-5.13M
2025Q1
628
200.01M
105.33%
-2.20M
2024Q4
586
190.11M
100.07%
-10.58M
2024Q3
566
185.43M
98.60%
-19.02M
2024Q2
541
188.12M
100.51%
-8.17M
2024Q1
529
185.29M
101.24%
-2.60M
2023Q4
525
179.04M
102.35%
-7.24M
2023Q3
519
174.99M
102.35%
-1.47M
2023Q2
503
162.75M
101.40%
-17.06M
2023Q1
513
164.96M
102.84%
-5.53M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Viking Global Investors LP
18.56M
9.77%
-3.50M
-15.87%
Jun 27, 2025
The Vanguard Group, Inc.
14.87M
7.83%
-177.77K
-1.18%
Mar 31, 2025
Kohlberg Kravis Roberts & Co. L.P.
13.26M
6.98%
-6.00M
-31.15%
May 12, 2025
BlackRock Institutional Trust Company, N.A.
11.18M
5.89%
-318.26K
-2.77%
Mar 31, 2025
Janus Henderson Investors
7.17M
3.78%
+2.26M
+46.13%
Mar 31, 2025
Kumar (Neil)
6.16M
3.25%
+5.69K
+0.09%
May 19, 2025
Aisling Capital Management LP
6.07M
3.2%
--
--
Mar 31, 2025
State Street Global Advisors (US)
5.75M
3.03%
-433.01K
-7.00%
Mar 31, 2025
Farallon Capital Management, L.L.C.
5.73M
3.02%
+1.54M
+36.62%
Mar 31, 2025
Capital Research Global Investors
4.67M
2.46%
+1.14M
+32.34%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Tema Oncology ETF
4.11%
Tema Heart & Health ETF
3.19%
Franklin Genomic Advancements ETF
2.39%
SPDR S&P Biotech ETF
2.15%
Virtus LifeSci Biotech Products ETF
2.1%
Direxion Daily S&P Biotech Bull 3X Shares
1.23%
Invesco Nasdaq Biotechnology ETF
0.91%
ProShares Ultra Nasdaq Biotechnology
0.91%
First Trust Mid Cap Growth AlphaDEX Fund
0.83%
iShares Health Innovation Active ETF
0.8%
View more
Tema Oncology ETF
Proportion4.11%
Tema Heart & Health ETF
Proportion3.19%
Franklin Genomic Advancements ETF
Proportion2.39%
SPDR S&P Biotech ETF
Proportion2.15%
Virtus LifeSci Biotech Products ETF
Proportion2.1%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.23%
Invesco Nasdaq Biotechnology ETF
Proportion0.91%
ProShares Ultra Nasdaq Biotechnology
Proportion0.91%
First Trust Mid Cap Growth AlphaDEX Fund
Proportion0.83%
iShares Health Innovation Active ETF
Proportion0.8%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
